Table 3.
Unadjusted and Adjusted Predictors Associated with Long‐Term Cardiac Mortality
| Unadjusted Hazard Ratio (95% CI) | P Value | Multivariable Adjusted Hazard Ratio (95% CI) | P Value | |
|---|---|---|---|---|
| Age (per y) | 1.08 (1.05–1.11) | <0.001 | 1.07 (1.04–1.10) | <0.001 |
| Male sex | 0.42 (0.24–0.74) | 0.003 | ||
| Diabetes mellitus | 3.39 (2.04–5.64) | <0.001 | 2.86 (1.70–4.80) | <0.001 |
| Previous MI | 1.68 (0.99–2.85) | 0.051 | ||
| Previous CABG | 2.54 (1.46–4.41) | 0.001 | ||
| Chronic kidney disease | 4.51 (2.57–7.92) | <0.001 | ||
| ACS | 1.70 (0.99–2.90) | 0.053 | ||
| LVEF <0.40 | 7.06 (3.88–12.85) | <0.001 | 5.27 (2.87–9.65) | <0.001 |
| Left anterior descending artery CTO | 1.81 (1.09–3.02) | 0.022 | ||
| Three‐vessel disease | 1.67 (0.98–2.84) | 0.058 | ||
| Successful CTO‐PCI | 0.33 (0.20–0.56) | <0.001 | ||
| Complete Revascularization | 0.20 (0.12–0.34) | <0.001 | 0.31 (0.18–0.54) | <0.001 |
| HPR on clopidogrel not “switched” | 3.46 (1.97–6.07) | <0.001 | 2.37 (1.33–4.20) | 0.003 |
| HPR on clopidogrel “switched” | 1.39 (0.60–3.25) | 0.436 | ||
| New P2Y12 antagonist therapy | 0.84 (0.46–1.52) | 0.578 | ||
| Year index | 0.99 (0.85–1.16) | 0.980 | ||
| Second generation DES | 0.90 (0.56–1.46) | 0.697 |
ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft; CTO, chronic total occlusion; DES, drug‐eluting stent; HPR, high platelet reactivity; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.